New drug combo aims to tame liver side effects of cancer immunotherapy
NCT ID NCT07663422
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining mycophenolate mofetil (MMF) with prednisone can better treat liver inflammation caused by checkpoint inhibitor cancer drugs. The trial includes adults with moderate to severe immune-related hepatitis who need to pause their cancer therapy. The main goal is to see if liver function improves within 30 days while safely reducing steroid use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mycophenolate mofetil plus prednisone
What this could lead to
If successful, this combination could become a standard first-line treatment for immune-related hepatitis, allowing patients to better manage this side effect and potentially continue cancer therapy.
What could go wrong
This is a small Phase 2 study with only 31 participants, so results may not apply broadly. The treatment carries risks of infection and other side effects, and it may not improve liver function as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE-MEDIATED HEPATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••